Vesalius Therapeutics

Pioneering a revolutionary platform to generate breakthrough treatments for common diseases

[Vesalius Therapeutics @VesaliusTx]

In Flagship's annual letter, Founder & CEO @NoubarAfeyan reflects on polyintelligence — the synthesis of human, machine, and nature's intelligence. At Vesalius, we’re tapping into polyintelligence to redefine how we think about and treat common diseases #FlagshipFounded.

[Flagship Pioneering @FlagshipPioneer]

Read or listen to Flagship Pioneering’s 2025 Annual Letter in which Founder & CEO @NoubarAfeyan explores polyintelligence — the synthesis of human, machine, and nature's intelligence, and how it is driving a new renaissance in science and technology: https://t.co/HeiyQYlDJe

Drawing inspiration from Leonardo da Vinci's integrated thinking, Noubar discusses how artificial intelligence will enhance our understanding of nature's adaptive genius in unprecedented ways. He highlights breakthroughs in biotechnology, agriculture, and machine intelligence, and how these polyintelligent innovations can tackle multifaceted challenges in health, climate, and beyond.

And for more on how polyintelligence is informing and guiding Flagship’s work, dive into our newly launched Special Section: https://t.co/rB2OUf2xJA

#BiggerLeaps #FlagshipStudio #JPM25

[Vesalius Therapeutics @VesaliusTx]

Vesalius redefines how we think about and treat common diseases. Read more about its recent alliance with @GSK to create breakthrough therapies for patients diagnosed with #Parkinson's disease. https://t.co/VkW0ha1fh1

[Vesalius Therapeutics @VesaliusTx]

Read more on the recently announced alliance between Vesalius and @GSK to create breakthrough therapies for patients diagnosed with #Parkinson's disease.
https://t.co/7Cua7PsLzn

#ParkinsonsDisease #ParkinsonsAwareness

[Vesalius Therapeutics @VesaliusTx]

Vesalius and @GSK share the conviction that targeting the causal factors of common diseases like #Parkinson’s disease is the key to developing breakthrough medicines faster and with a higher probability of success. Read more: https://t.co/I6JdYLBsh4
#ParkinsonsDisease

[Vesalius Therapeutics @VesaliusTx]

Companies pioneering original science are essential to bring about new medicines for patients. We are proud to be part of the #FlagshipFounded ecosystem of companies and the many more to come. https://t.co/VNeUFZBW0S

[Vesalius Therapeutics @VesaliusTx]

Our CEO @CPAustinMD describes how Vesalius has developed the first precision platform for common diseases and what’s ahead for the company as its lead candidates approach the clinic

https://t.co/6JPvx94Xdp

[Vesalius Therapeutics @VesaliusTx]

Our CEO @CPAustinMD joins colleagues at the @FlagshipPioneer Studio where he discusses how we’re pioneering a radical new approach to common disease drug development. #FlagshipJPM #JPM2024
https://t.co/qNO2ZzI3hx

[Vesalius Therapeutics @VesaliusTx]

In Flagship’s 2024 Annual Letter, founder and CEO @NoubarAfeyan reflects on navigating through polycrisis and what it will take to make bigger leaps for patients and the planet. Read his annual newsletter below: #FlagshipFounded https://t.co/qJSkk5h9g0

[Vesalius Therapeutics @VesaliusTx]

We are proud to be #FlagshipFounded and part of an ecosystem taking bold scientific leaps and building breakthrough companies like Vesalius.

[Flagship Pioneering @FlagshipPioneer]

At Flagship, we believe the profound, urgent challenges of today and tomorrow will be best met by taking bold scientific leaps. #WeAreFlagship

[Vesalius Therapeutics @VesaliusTx]

Discover how @CPAustinMD and his team plan to radically change how we develop therapies for serious common diseases. Say goodbye to the one-size-fits-all approach! Read this inspiring article in Lifestyles Magazine. #LifestylesMagazine #FutureOfHealth https://t.co/1pHJhfAFjQ

[Vesalius Therapeutics @VesaliusTx]

We’ll be at #ISSCR2023. Hear what @CPAustinMD has to say about the application and scalability of stem cell technologies which could redefine drug discovery. #StemCells https://t.co/Az2oTZPqzr

[Vesalius Therapeutics @VesaliusTx]

This week at #LongwoodHealthcareLeaders, Chris Cotsapas will lead a discussion on Data Science Evolution & Enablement, and @CPAustinMD will share insights on Accelerating Drug Development. Join us in revolutionizing healthcare innovation! https://t.co/cyOr0aBgrU #DrugDevelopment

[Vesalius Therapeutics @VesaliusTx]

Done under the auspices of the National Academy of Medicine, this work provides a detailed roadmap to increasing the efficiency, effectiveness, safety, and diversity of clinical trials in the U.S. https://t.co/RlpqtwpoSX

[Vesalius Therapeutics @VesaliusTx]

Congratulations to our CEO, Christopher Austin (@CPAustinMD), and the rest of the authors of this recent publication outlining 'A Framework for Assessing Clinical Trial Site Readiness'.

[Vesalius Therapeutics @VesaliusTx]

Tomorrow, our CEO @CPAustinMD will participate in a panel at the @MilkenInstitute 2023 Global Conference. The panel will discuss what the future holds for biotech investment. Join live here: https://t.co/G2cZyNe2C7

[Vesalius Therapeutics @VesaliusTx]

We are inspired every day by audacious "what if …" questions that challenge current assumptions, which is why we loved this conversation between our CEO @CPAustinMD and @WSJ health reporter @AmyDMarcus. https://t.co/VOj2ZksXYW

[Vesalius Therapeutics @VesaliusTx]

Our CEO, Christopher Austin, was featured in a chapter of @AmyDMarcus’ new book “We the Scientists”. It was only fitting that he show up to support her local event at the Brookline Booksmith this week.

[Vesalius Therapeutics @VesaliusTx]

@AmyDMarcus published an essay in the @WSJ this weekend on how patients are working with researchers in new & creative ways to improve medicine. It’s an idea we hold dear in our work. It was an honor for our CEO Christopher Austin to provide perspective. https://t.co/dBjuJldjFM

[Amy Dockser Marcus @AmyDMarcus]

We the Scientists is about a powerful idea-- that we, the scientists, doctors, families, patients, regulators, and government officials, can work together to find cures and advance science. @wsj @riverheadbooks

[Vesalius Therapeutics @VesaliusTx]

This paradigm – of including patients earlier and more prominently in the drug development process – is something we’re applying to our work at Vesalius. Check out the book – it's a fantastic read. (2/2)

[Vesalius Therapeutics @VesaliusTx]

@AmyDMarcus’ new book, “We the Scientists,” was officially released today. The book describes a new drug development paradigm that developed when parents, doctors, & researchers joined forces to tackle a devastating disease. Our CEO Christopher Austin was part of that team. (1/2)